JP2007070265A - Composition for improving lipid metabolism - Google Patents
Composition for improving lipid metabolism Download PDFInfo
- Publication number
- JP2007070265A JP2007070265A JP2005257170A JP2005257170A JP2007070265A JP 2007070265 A JP2007070265 A JP 2007070265A JP 2005257170 A JP2005257170 A JP 2005257170A JP 2005257170 A JP2005257170 A JP 2005257170A JP 2007070265 A JP2007070265 A JP 2007070265A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lipid metabolism
- buckwheat
- improving lipid
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- TULAVYIIXUZUOJ-WHCFPLFHSA-N CC([C@@H](C([C@@H]1O)O)O)O[C@H]1OCC([C@H]([C@@](C)(C1O)O)O)O[C@H]1OC1=C(c(cc2)cc(O)c2O)Oc2cc(O)cc(O)c2C1=O Chemical compound CC([C@@H](C([C@@H]1O)O)O)O[C@H]1OCC([C@H]([C@@](C)(C1O)O)O)O[C@H]1OC1=C(c(cc2)cc(O)c2O)Oc2cc(O)cc(O)c2C1=O TULAVYIIXUZUOJ-WHCFPLFHSA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、脂質代謝改善用組成物に関するものである。 The present invention relates to a composition for improving lipid metabolism.
肥満は、過食や運動不足などが原因で発症し、高血圧症、糖尿病、高脂血症、動脈硬化、脳血管障害、虚血性心疾患、腎障害など、生活習慣病のリスクファクターと考えられている。肥満とは脂肪組織重量の増加した状態で、エネルギー摂取が消費より過剰になることから生じる。また、欧米人に比べ、日本人は内臓脂肪型肥満になりやすい。また、内臓脂肪型肥満及び脂質代謝を改善することにより、生活習慣病を予防できると考えられている。 Obesity is caused by overeating or lack of exercise, and is considered a risk factor for lifestyle-related diseases such as hypertension, diabetes, hyperlipidemia, arteriosclerosis, cerebrovascular disorder, ischemic heart disease, and renal disorder. Yes. Obesity results from an increase in adipose tissue weight and an excess of energy intake over consumption. Compared to Westerners, Japanese people are more likely to have visceral fat obesity. It is also considered that lifestyle-related diseases can be prevented by improving visceral fat obesity and lipid metabolism.
このような背景の下、本発明者らは、種々の植物由来の抽出物について、そばのエタノール抽出物に着目するに至った。
そして、各種の実験を行った結果、この抽出物に含まれるルチンが、脂質代謝を改善し、これにより肥満を防止することを見出した。
本発明は、肥満の防止にきわめて有効なそば由来のおよび脂質代謝改善剤及びそれらの製造方法を提供することを目的とする。
Under such a background, the present inventors came to pay attention to buckwheat ethanol extract for extracts derived from various plants.
As a result of various experiments, it was found that rutin contained in this extract improves lipid metabolism and thereby prevents obesity.
It is an object of the present invention to provide buckwheat-derived and lipid metabolism improving agents that are extremely effective in preventing obesity and methods for producing them.
上記課題を解決するために、本発明の脂質代謝改善用組成物は、ルチンを有効成分とすることを特徴とする。
また、本発明の脂質代謝改善用組成物は、ソバ（蕎麦）の葉部、茎部、花部及び種子のうちに少なくとも一種を含む地上部の溶媒抽出物を含有することを特徴とする。
更に、前記溶媒抽出物の抽出溶媒が含水エタノールであることが好ましい。
In order to solve the above problems, the composition for improving lipid metabolism of the present invention is characterized by containing rutin as an active ingredient.
The composition for improving lipid metabolism of the present invention is characterized by containing an above-ground solvent extract containing at least one of leaves, stems, flowers and seeds of buckwheat (buckwheat).
Furthermore, it is preferable that the extraction solvent of the solvent extract is hydrous ethanol.
以下、本発明の実施の形態について、詳細に説明する。 Hereinafter, embodiments of the present invention will be described in detail.
本発明の脂質代謝改善用組成物は、ルチンを有効成分とすることを特徴とする。ルチンとは、下記の化学式にて示されるフラボノール配糖体の一種である。 The composition for improving lipid metabolism of the present invention is characterized by containing rutin as an active ingredient. Rutin is a kind of flavonol glycoside represented by the following chemical formula.
上記ルチンを抽出する原料として、特に限定されないが、ミカン科のヘンルーダ(Ruta graveolens LINNE)、マメ科のエンジュ（Sophra japonica LINNE)の花蕾、及びタデ科のそば等から得ることができるが、タデ科のそばから得ることが好ましい。
ソバ（蕎麦）は、タデ科の一年草で、その種実は“そば粉”の原料として知られている。三角形の葉を互生し，葉柄基部に茎を取り囲むサヤ状の托葉をもつ。茎は片側にくぼみをもつ円筒形であり、茎の先端数節に、総状花序で多数の花をつける。
The raw material for extracting rutin is not particularly limited. It is preferable to obtain from soba.
Buckwheat (soba) is an annual plant of the Tedaceae family, and its seed is known as a raw material for “buckwheat flour”. Triangular leaves alternate with each other and have a Saya-shaped bamboo leaf surrounding the stem at the base of the petiole. The stem has a cylindrical shape with a depression on one side, and a large number of flowers are attached at the tip of the stem with a general inflorescence.
本発明の脂質代謝改善用組成物を抽出するための原料としては、主に、ソバの葉部、茎部、花部及び種子のうちの少なくとも一種含む地上部を用いる。即ち、葉部、茎部、花部及び種子の混合物を使用してもよいし、葉部、茎部、花部及び種子のいずれかを単独で使用してもよい。また、根部等を更に混合したものを抽出原料として使用してもよい。 As a raw material for extracting the composition for improving lipid metabolism of the present invention, a ground part containing at least one of buckwheat leaf part, stem part, flower part and seed is mainly used. That is, a mixture of leaves, stems, flowers and seeds may be used, or any of leaves, stems, flowers and seeds may be used alone. Moreover, you may use what mixed the root part etc. further as an extraction raw material.
ソバの品種は、作期に応じて夏ソバ、秋ソバあるいは両者の中間型などに分けられており、また、栽培種としては、本種：Ｆａｇｏｐｙｒｕｍ ｅｓｃｕｌｅｎｔｕｍ Ｍｏｅｎｃｈの他、耐冷性のダッタンソバ：Ｆ．ｔａｔａｒｉｃｕｍ Ｇａｅｒｔｎ．（ニガソバともいう。）、多年生のシャクチリソバ：Ｆ．ｃｙｍｏｓｕｍ Ｍｅｉｓｎ．（シュッコンソバともいう。） などがある。
本発明の脂質代謝改善用組成物を抽出するための原料としては、本種を用いるのが好ましいが、上記のいずれの品種であっても使用することができる。また、産地等も限定されない。
The buckwheat varieties are divided into summer buckwheat, autumn buckwheat, or an intermediate type between the two depending on the cropping season. tataricum Gaertn. (Also referred to as “Nigasoba”), perennial Shakuchirisoba: F. cymosum Meisn. (It is also referred to as Sukkon Soba.)
As a raw material for extracting the composition for improving lipid metabolism of the present invention, this species is preferably used, but any of the above varieties can be used. Also, the production area is not limited.
ソバの葉部、茎部、花部等の抽出原料は、生のままで使用することもできるが、好ましくは、乾燥物を使用する。乾燥方法としては、天日で行う方法の他、陰干し、風乾、熱風乾燥、冷凍乾燥など公知の方法で乾燥することができる。
また、抽出原料は、粉砕機等により数ｍｍ以下のサイズに裁断または粉砕した粉砕物を用いるとよい。このような粉砕物を使用することにより、有効成分が抽出されやすくなる。
Extract raw materials such as buckwheat leaf part, stem part, flower part and the like can be used as they are, but a dry product is preferably used. As a drying method, it can be dried by a publicly known method such as shade drying, air drying, hot air drying, freeze drying and the like.
The extraction raw material may be a pulverized product cut or pulverized into a size of several mm or less by a pulverizer or the like. Use of such a pulverized product facilitates extraction of active ingredients.
本発明の脂質代謝改善用組成物を抽出するための溶媒としては、水、メタノール、エタノール、イソプロピルアルコール、アセトン、１，３−ブチレングリコール、エチレングリコール、プロピレングリコール、グリセリン、酢酸エチル等の溶媒を使用するとよい。これらの溶媒を２種以上混合したものを用いることもできる。好ましくは、水または含水エタノールを抽出溶媒として用いると、有効成分が効率よく抽出される。特に、含水エタノールは、抽出の際に有効成分の活性を保ちやすく、抽出物の食品使用における安全面の上でも好ましい抽出溶媒である。 As a solvent for extracting the composition for improving lipid metabolism of the present invention, a solvent such as water, methanol, ethanol, isopropyl alcohol, acetone, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, and ethyl acetate is used. It is good to use. A mixture of two or more of these solvents can also be used. Preferably, when water or hydrous ethanol is used as the extraction solvent, the active ingredient is efficiently extracted. In particular, hydrous ethanol is an extraction solvent that is easy to maintain the activity of the active ingredient during extraction and is preferable from the viewpoint of safety of the extract in food use.
抽出溶媒として水を使用する場合には、抽出温度２０〜１００℃、好ましくは８０〜１００℃程度で行うとよい。これは、抽出温度が低すぎると、有効成分が抽出されにくいためである。抽出用の水の種類は、特に限定されず、水道水、蒸留水、ミネラル水、アルカリイオン水等を使用することができる。好ましくは、抽出溶媒として、深層水（海洋深層水）を使用するとよい。 When water is used as the extraction solvent, the extraction temperature is 20 to 100 ° C., preferably about 80 to 100 ° C. This is because if the extraction temperature is too low, it is difficult to extract active ingredients. The kind of water for extraction is not particularly limited, and tap water, distilled water, mineral water, alkaline ionized water and the like can be used. Preferably, deep water (deep ocean water) is used as the extraction solvent.
抽出溶媒として含水エタノールを使用する場合、エタノール濃度３０〜９０％（容量比）であることが好ましい。３０％（容量比）程度よりも少ないか、９０％（容量比）を超えると、有効成分の抽出量が低下しやすくなるからである。また、抽出温度は、２０〜８０℃、好ましくは５０〜８０℃程度で行うとよい。なお、含水エタノール抽出は、有効成分の含有率を向上させるため、種々の濃度で繰り返すとよい。 When hydrous ethanol is used as the extraction solvent, the ethanol concentration is preferably 30 to 90% (volume ratio). This is because if the amount is less than about 30% (volume ratio) or exceeds 90% (volume ratio), the extraction amount of the active ingredient tends to decrease. The extraction temperature is 20 to 80 ° C, preferably about 50 to 80 ° C. In addition, the water-containing ethanol extraction may be repeated at various concentrations in order to improve the content of the active ingredient.
本発明の脂質代謝改善用組成物の抽出方法としては、連続抽出、浸漬抽出、向流抽出、超臨界抽出など任意の方法を採用することができ、室温ないし還流加熱下において任意の装置を使用することができる。 As a method for extracting the composition for improving lipid metabolism of the present invention, any method such as continuous extraction, immersion extraction, countercurrent extraction, supercritical extraction and the like can be adopted, and any apparatus is used at room temperature or under reflux heating. can do.
具体的な方法としては、抽出溶媒を満たした処理槽に抽出原料を投入し、攪拌しながら有効成分を溶出させる。例えば、抽出溶媒として水または含水エタノールを用いる場合には、抽出原料の５〜１００倍量程度（重量比）の極性溶媒を使用し、３０分〜２時間程度抽出を行う。溶媒中に有効成分を溶出させた後、ろ過して抽出残渣を除くことによって、抽出液を得る。その後、常法に従って抽出液に希釈、濃縮、乾燥、精製等の処理を施し、脂質代謝改善用組成物とする。
なお、精製方法としては、例えば、活性炭処理、樹脂吸着処理、イオン交換樹脂、液−液向流分配等の方法が挙げられるが、食品等に添加する場合には大量に使用するものではないから、未精製のままで使用してもよい。
As a specific method, an extraction raw material is put into a treatment tank filled with an extraction solvent, and an active ingredient is eluted while stirring. For example, when water or water-containing ethanol is used as the extraction solvent, the extraction is performed for about 30 minutes to 2 hours using a polar solvent of about 5 to 100 times (weight ratio) of the extraction raw material. The active ingredient is eluted in the solvent, and then filtered to remove the extraction residue to obtain an extract. Thereafter, the extract is subjected to treatments such as dilution, concentration, drying and purification according to a conventional method to obtain a composition for improving lipid metabolism.
Examples of the purification method include activated carbon treatment, resin adsorption treatment, ion exchange resin, liquid-liquid countercurrent distribution, and the like, but they are not used in large quantities when added to foods. It may be used unpurified.
本発明の脂質代謝改善用組成物は、飲食品に含有させることができる。例えば、菓子類（ガム、キャンディー、キャラメル、チョコレート、クッキー、スナック、ゼリー、グミ、錠菓等）、麺類（そば、うどん、ラーメン等）、乳製品（ミルク、アイスクリーム、ヨーグルト等）、調味料（味噌、醤油等）、スープ類、飲料（ジュース、コーヒー、紅茶、茶、炭酸飲料、スポーツ飲料等）をはじめとする一般食品や、健康食品（錠剤、カプセル等）、栄養補助食品（栄養ドリンク等）等が挙げられる。 The composition for improving lipid metabolism of the present invention can be contained in a food or drink. For example, confectionery (gum, candy, caramel, chocolate, cookies, snacks, jelly, gummi, tablet confectionery, etc.), noodles (soba, udon, ramen, etc.), dairy products (milk, ice cream, yogurt, etc.), seasonings (Miso, soy sauce, etc.), soups, beverages (juice, coffee, tea, tea, carbonated drinks, sports drinks, etc.), general foods, health foods (tablets, capsules, etc.), nutritional supplements (nutrient drinks) Etc.).
インスタント食品に本発明の脂質代謝改善用組成物を添加してもよい。例えば、脂質代謝改善用組成物を粉末セルロースとともにスプレードライまたは凍結乾燥したものを、粉末、顆粒、打錠または溶液にすることで容易に飲食品に含有させることができる。
また、本発明の脂質代謝改善用組成物を、例えば、油脂、エタノール、プロピレングリコール、グリセリンあるいはこれらの混合物に溶解して液状にし、飲料に添加するか、固形食品に添加することが可能である。さらに、必要に応じてアラビアガム、デキストリン等のバインダーと混合して粉末状あるいは顆粒状にし、飲料に添加するか固形食品に添加することも可能である。
You may add the composition for lipid metabolism improvement of this invention to an instant foodstuff. For example, the composition for improving lipid metabolism, which is spray-dried or freeze-dried with powdered cellulose, can be easily contained in a food or drink by making it into a powder, granule, tablet or solution.
In addition, the lipid metabolism improving composition of the present invention can be dissolved in, for example, fats and oils, ethanol, propylene glycol, glycerin or a mixture thereof to be liquid and added to beverages or added to solid foods. . Furthermore, if necessary, it can be mixed with a binder such as gum arabic or dextrin to form a powder or granules, which can be added to beverages or added to solid foods.
本発明の脂質代謝改善用組成物を飲食品に適用する場合の添加量としては、病気予防や健康維持が目的であるので、飲食品に対して脂質代謝改善用組成物の含量が合計１〜２０重量％であるのが好ましい。 When the composition for improving lipid metabolism of the present invention is applied to foods and drinks, since the purpose is to prevent disease and maintain health, the total content of the composition for improving lipid metabolism is 1 to It is preferably 20% by weight.
本発明の脂質代謝改善用組成物は、医薬品の有効成分として使用してもよい。本発明による「医薬品」は、病気を予防、治療するものであれば特に限定されず、薬事法上の医薬品および医薬部外品のいずれであってもよい。
医薬品としての脂質代謝改善用組成物の投与方法は、経口投与することが好ましい。一般的には錠剤、丸剤、軟・硬カプセル剤、細粒剤、散剤、顆粒剤、液剤等の形態とすることができる。
また、本発明の医薬品を非経口投与してもよい。非経口剤として投与する場合、溶液の状態、または分散剤、懸濁剤、安定剤などを添加した状態で、注射剤、坐剤などの形態とすることができる。
You may use the composition for lipid metabolism improvement of this invention as an active ingredient of a pharmaceutical. The “pharmaceutical product” according to the present invention is not particularly limited as long as it prevents or treats a disease, and may be either a pharmaceutical product or a quasi-drug according to the Pharmaceutical Affairs Law.
The method for administering the composition for improving lipid metabolism as a pharmaceutical is preferably administered orally. Generally, it can be in the form of tablets, pills, soft / hard capsules, fine granules, powders, granules, liquids and the like.
Moreover, you may administer the pharmaceutical of this invention parenterally. When administered as a parenteral preparation, it can be in the form of an injection, a suppository, or the like in the form of a solution or with a dispersion, suspension, stabilizer or the like added.
脂質代謝改善用組成物の投与量は、年齢、体重、症状、治療効果、投与方法、処理時間等により異なるが、通常成人一人あたり、１回に１ｍｇ〜１０００ｍｇの範囲で、１日１回から数回経口投与されるか、または、１回に１００μｇ〜１００ｍｇの範囲で、１日１回から数回非経口投与される。
なお、投与量は種々の条件で異なるので、前記投与量より少ない量で十分な場合もあるし、また、範囲を超えて投与する必要のある場合もある。
The dose of the composition for improving lipid metabolism varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but is usually in the range of 1 mg to 1000 mg per adult, once a day. It is administered orally several times or administered parenterally once to several times a day in the range of 100 μg to 100 mg at a time.
In addition, since the dose varies depending on various conditions, a dose smaller than the above dose may be sufficient, or it may be necessary to administer beyond the range.
以下、本発明を具体化した実施例について詳細に説明する。
〔ソバエキスの製造〕
ソバの葉部と茎部とからなる乾燥物（花部もわずかに含まれる。）を入手し、粉砕機により粉砕した。この粉砕物５ｋｇを抽出用の原料として使用した。
原料粉砕物にエタノール濃度９０％（容量比）の含水エタノールを約１０倍量加え、２時間加熱還流して抽出を行った。その後、含水エタノール抽出液をろ過して残渣を除き、ろ液の溶媒を除去してソバ抽出物（ソバエキス４００ｇ）を得た。
Hereinafter, embodiments embodying the present invention will be described in detail.
[Manufacture of buckwheat extract]
A dried product comprising a buckwheat leaf portion and a stem portion (including a small amount of flower portion) was obtained and pulverized by a pulverizer. 5 kg of this pulverized product was used as a raw material for extraction.
About 10 times the amount of hydrous ethanol having an ethanol concentration of 90% (volume ratio) was added to the pulverized raw material, and extraction was performed by heating under reflux for 2 hours. Thereafter, the aqueous ethanol extract was filtered to remove the residue, and the solvent of the filtrate was removed to obtain a buckwheat extract (buckwheat extract 400 g).
〔ソバエキスの機能性試験〕
製造されたソバエキスの機能性を検討するために以下の動物実験を行った。
即ち、4週齢の雄性Sprague-Dawleyラット（以下SDラットという）を、室温22±1℃、室温55±5％、8：00〜20：00点灯のライトサイクルの動物飼育室で飼育した。
最初5日間はMF固形飼料を与えて予備飼育を行った。その後、ラットの体重に群間で差がないように群分けし、以下の試験食を4週間自由摂食させた。
[Function test of buckwheat extract]
In order to examine the functionality of the produced buckwheat extract, the following animal experiment was conducted.
That is, 4 weeks old male Sprague-Dawley rats (hereinafter referred to as SD rats) are housed in an animal breeding room with a light cycle of room temperature 22 ± 1 ° C, room temperature 55 ± 5%, 8: 00 〜 20: 00. did.
For the first 5 days, MF solid feed was given and preliminary breeding was performed. Thereafter, the rats were divided into groups so that there was no difference in the body weight between the groups, and the following test meals were fed freely for 4 weeks.
試験食は、AIN-93G組成に基づいた純化食をコントロール食とした。飼料の重量組成（g/kg）は、カゼイン200、コーン油50、ミネラル混合（AIN-93-MX）35、ビタミン混合（AIN-93-VX）10、セルロース50、重酒石酸コリン2、α-コーンスターチ132、ショ糖100、L-シスチン3、コレステロール5、コール酸ナトリウム1.25、TBHQ0.014およびコーンスターチで1000とした。ソバの葉添加群には、ソバエキスを飼料総重量の1％添加し、その添加量分のコーンスターチ量を減じた。飼育期間中、摂食量は毎日、体重は1日おきに測定した。 As the test meal, a purified meal based on the AIN-93G composition was used as a control meal. The weight composition of the feed (g / kg) is: casein 200, corn oil 50, mineral mixture (AIN-93-MX) 35, vitamin mixture (AIN-93-VX) 10, cellulose 50, choline bitartrate 2, α- Corn starch 132, sucrose 100, L-cystine 3, cholesterol 5, sodium cholate 1.25, TBHQ0.014 and corn starch were set to 1000. In the buckwheat leaf addition group, 1% of the total weight of the buckwheat extract was added, and the amount of corn starch was reduced by the added amount. During the breeding period, food intake was measured every day and body weight was measured every other day.
ソバエキスは、SDラットの血清コレステロール、血清中性脂肪および肝臓中性脂肪濃度を効果的に低下させた。結果を表１に示す。 Buckwheat extract effectively reduced serum cholesterol, serum triglyceride and liver triglyceride levels in SD rats. The results are shown in Table 1.
血清や肝臓の中性脂肪濃度は、肝臓の脂肪合成や分解による影響を大きく受ける。そこで、肝臓脂肪合成関連酵素の活性を測定した。ソバエキスは、脂肪酸合成に関与する肝臓サイトゾル画分のFatty acid synthase活性および脂肪合成に関与する肝臓ミクロソーム画分のPhosphatidic acid phosphohydrolase活性を著しく低下させた。結果を表２に示す。 Serum and liver neutral fat concentrations are greatly affected by liver fat synthesis and degradation. Therefore, the activity of liver fat synthesis-related enzyme was measured. Buckwheat extract significantly reduced the Fatty acid synthase activity of the liver cytosol fraction involved in fatty acid synthesis and the Phosphatidic acid phosphohydrolase activity of the liver microsomal fraction involved in fat synthesis. The results are shown in Table 2.
これらの結果から、ソバエキスは肝臓Fatty acid synthase活性およびPhosphatidic acid phosphohydrolase活性を低下させることで肝臓脂肪合成を抑制することにより肝臓および血清中性脂肪濃度を低下させることが明らかとなった。 From these results, it was clarified that buckwheat extract reduces liver and serum neutral fat levels by suppressing liver fat synthesis by reducing liver Fatty acid synthase activity and Phosphatidic acid phosphohydrolase activity.
〔配合例〕
以下に脂質代謝改善用組成物として用いられるソバエキスの配合例を示す。尚、下記配合例は、発明の要旨を限定するものではなく、脂質代謝改善用組成物として効果があれば、下記配合例に限定されない。
配合例１：チューインガム
砂糖 ５３．０重量％
ガムベース ２０．０
グルコース １０．０
水飴 １６．０
香料 ０．５
ソバエキス ０．５
１００．０重量％
[Example of formulation]
The following is a blending example of buckwheat extract used as a composition for improving lipid metabolism. The following formulation examples do not limit the gist of the invention and are not limited to the following formulation examples as long as they are effective as a composition for improving lipid metabolism.
Formulation Example 1: Chewing gum
53.0% by weight sugar
Gum base 20.0
Glucose 10.0
Minamata 16.0
Fragrance 0.5
Buckwheat extract 0.5
100.0% by weight
配合例２：グミ
還元水飴 ４０．０重量％
グラニュー糖 ２０．０
ブドウ糖 ２０．０
ゼラチン ４．７
水 ９．６８
ウメ果汁 ４．０
ウメフレーバー ０．６
色素 ０．０２
ソバエキス １．０
１００．０重量％
Formulation Example 2: Gummy
Reduced water tank 40.0% by weight
Granulated sugar 20.0
Glucose 20.0
Gelatin 4.7
Water 9.68
Ume Juice 4.0
Ume Flavor 0.6
Dye 0.02
Buckwheat extract 1.0
100.0% by weight
配合例３：キャンディー
砂糖 ５０．０重量％
水飴 ３３．０
水 １４．４
有機酸 ２．０
香料 ０．２
ソバエキス ０．４
１００．０重量％
Formulation Example 3: Candy
50.0% by weight sugar
Minamata 33.0
Water 14.4
Organic acid 2.0
Fragrance 0.2
Buckwheat extract 0.4
100.0% by weight
配合例４：ヨーグルト（ハード・ソフト）
牛乳 ４１．５重量％
脱脂粉乳 ５．８
砂糖 ８．０
寒天 ０．１５
ゼラチン ０．１
乳酸菌 ０．００５
ソバエキス ０．４
香料 微量
水 残余
１００．０重量％
Formulation Example 4: Yogurt (hard / soft)
41.5% by weight of milk
Nonfat dry milk 5.8
Sugar 8.0
Agar 0.15
Gelatin 0.1
Lactic acid bacteria 0.005
Buckwheat extract 0.4
Perfume
Water residue
100.0% by weight
配合例５：ソフトカプセル
玄米胚芽油 ８７．０重量％
乳化剤 １２．０
ソバエキス １．０
１００．０重量％
Formulation Example 5: Soft capsule
Brown rice germ oil 87.0% by weight
Emulsifier 12.0
Buckwheat extract 1.0
100.0% by weight
配合例６：コーヒー飲料（液状）
焙煎コーヒー豆 ６．０重量％
砂糖 ６．０
重曹 ０．２
乳化剤 ０．１５
ソバエキス １．０
水 残余
１００．０重量％
Formulation Example 6: Coffee beverage (liquid)
Roasted coffee beans 6.0% by weight
Sugar 6.0
Baking soda 0.2
Emulsifier 0.15
Buckwheat extract 1.0
Water residue
100.0% by weight
配合例７：コーヒー飲料（粉末）
インスタントコーヒー ９０．０重量％
脱脂乳 ７．０
ソバエキス ３．０
１００．０重量％
Formulation Example 7: Coffee drink (powder)
Instant coffee 90.0% by weight
Skim milk 7.0
Buckwheat extract 3.0
100.0% by weight
配合例８：清涼飲料
果糖ブドウ糖液糖 ３０．０重量％
乳化剤 ０．５
ソバエキス ０．０５
香料 適量
精製水 残余
１００．０重量％
Formulation Example 8: Soft drink
Fructose glucose liquid sugar 30.0% by weight
Emulsifier 0.5
Buckwheat extract 0.05
Perfume
Purified water residue
100.0% by weight
配合例９：錠剤
乳糖 ５４．０重量％
結晶セルロース ３０．０
澱粉分解物 １０．０
グリセリン脂肪酸エステル ５．０
ソバエキス １．０
１００．０重量％
Formulation Example 9: Tablet
Lactose 54.0% by weight
Crystalline cellulose 30.0
Starch degradation product 10.0
Glycerin fatty acid ester 5.0
Buckwheat extract 1.0
100.0% by weight
配合例１０：錠菓
砂糖 ７６．４重量％
グルコース １９．０
ショ糖脂肪酸エステル ０．２
ソバエキス ０．５
精製水 ３．９
１００．０重量％
Formulation Example 10: Tablet
76.4% by weight of sugar
Glucose 19.0
Sucrose fatty acid ester 0.2
Buckwheat extract 0.5
Purified water 3.9
100.0% by weight
以上、説明したとおり、ソバエキスは、脂質代謝改善に効果を有する飲食品や医薬品として十分利用できるものである。
As described above, buckwheat extract can be sufficiently used as a food or drink or a medicine having an effect on lipid metabolism improvement.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005257170A JP2007070265A (en) | 2005-09-05 | 2005-09-05 | Composition for improving lipid metabolism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005257170A JP2007070265A (en) | 2005-09-05 | 2005-09-05 | Composition for improving lipid metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007070265A true JP2007070265A (en) | 2007-03-22 |
Family
ID=37932029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005257170A Pending JP2007070265A (en) | 2005-09-05 | 2005-09-05 | Composition for improving lipid metabolism |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007070265A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010037319A (en) * | 2008-08-08 | 2010-02-18 | Shizuokaken Koritsu Daigaku Hojin | Visceral fat accumulation suppressor |
| KR101330718B1 (en) | 2012-09-24 | 2013-11-20 | 사단법인 임금님표 이천브랜드관리본부 | Method of manufacturing rice including rutin from fagopyrum tataricum sprout using supercritical processing and rice including rutin manufactured by the method |
| JP2014097987A (en) * | 2013-12-17 | 2014-05-29 | Shizuokaken Koritsu Daigaku Hojin | Visceral fat accumulation inhibitor |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05292918A (en) * | 1991-02-26 | 1993-11-09 | Oomiya Yakugyo Kk | Functional health food |
| JPH1084891A (en) * | 1996-08-02 | 1998-04-07 | Shotei Cho | Health food containing kangra buckwheat or oats or both thereof as effective components |
| JPH10218786A (en) * | 1997-02-07 | 1998-08-18 | Amino Atsupu Kagaku:Kk | Medicine comprising buckwheat chaff extract as active ingredient |
| JP2002080362A (en) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar-dependent gene transcription activator |
| JP2002524522A (en) * | 1998-09-15 | 2002-08-06 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | Composition containing rutin and quercetin for prevention or treatment of diseases caused by high blood lipid levels |
| WO2004027074A2 (en) * | 2002-09-23 | 2004-04-01 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture | Extraction, purification and conversion of flavonoids from plant biomass |
| JP2004305202A (en) * | 2003-04-09 | 2004-11-04 | Pekin Kunyo Aiba Kagi Yugenkoshi | Method for processing beverage given by using tartary buckwheat as raw material |
| JP2005137217A (en) * | 2003-11-04 | 2005-06-02 | Alps Yakuhin Kogyo Kk | Feed additive for poultry, poultry-meat quality improver, neutral-fat depressant for poultry, productivity improver for poultry, and poultry feed containing the additive and the agents |
-
2005
- 2005-09-05 JP JP2005257170A patent/JP2007070265A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05292918A (en) * | 1991-02-26 | 1993-11-09 | Oomiya Yakugyo Kk | Functional health food |
| JPH1084891A (en) * | 1996-08-02 | 1998-04-07 | Shotei Cho | Health food containing kangra buckwheat or oats or both thereof as effective components |
| JPH10218786A (en) * | 1997-02-07 | 1998-08-18 | Amino Atsupu Kagaku:Kk | Medicine comprising buckwheat chaff extract as active ingredient |
| JP2002524522A (en) * | 1998-09-15 | 2002-08-06 | コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー | Composition containing rutin and quercetin for prevention or treatment of diseases caused by high blood lipid levels |
| JP2002080362A (en) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar-dependent gene transcription activator |
| WO2004027074A2 (en) * | 2002-09-23 | 2004-04-01 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture | Extraction, purification and conversion of flavonoids from plant biomass |
| JP2004305202A (en) * | 2003-04-09 | 2004-11-04 | Pekin Kunyo Aiba Kagi Yugenkoshi | Method for processing beverage given by using tartary buckwheat as raw material |
| JP2005137217A (en) * | 2003-11-04 | 2005-06-02 | Alps Yakuhin Kogyo Kk | Feed additive for poultry, poultry-meat quality improver, neutral-fat depressant for poultry, productivity improver for poultry, and poultry feed containing the additive and the agents |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010037319A (en) * | 2008-08-08 | 2010-02-18 | Shizuokaken Koritsu Daigaku Hojin | Visceral fat accumulation suppressor |
| KR101330718B1 (en) | 2012-09-24 | 2013-11-20 | 사단법인 임금님표 이천브랜드관리본부 | Method of manufacturing rice including rutin from fagopyrum tataricum sprout using supercritical processing and rice including rutin manufactured by the method |
| JP2014097987A (en) * | 2013-12-17 | 2014-05-29 | Shizuokaken Koritsu Daigaku Hojin | Visceral fat accumulation inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6640392B2 (en) | Obesity control composition | |
| JP5261808B2 (en) | Fat accumulation inhibitor, medicine and method for newly imparting fat accumulation inhibitory action | |
| JP4684556B2 (en) | Method for producing SDG and its blended food and drink | |
| KR20160144791A (en) | Composition for relieving menopausal symptom | |
| US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| JP2018070570A (en) | Lindera plant extract | |
| KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
| JP2009247254A (en) | Health drink | |
| JP2008044872A (en) | Health food containing isolariciresinol, blood cholesterol-reducing agent and body fat-reducing agent | |
| US20060210659A1 (en) | Anti-obesity agent | |
| JP2007070265A (en) | Composition for improving lipid metabolism | |
| JP2007070263A (en) | Composition for preventing diabetes mellitus | |
| KR101075554B1 (en) | Composition for the prevention and treatment of postmenopausal syndrome containing extracts or fractions of Aceriphyllum rossii as an effective ingredient | |
| JP5177676B2 (en) | Fat absorption inhibitor and food and drink using the same | |
| KR101910099B1 (en) | Compositions for improving lipid metabolism or anti-obesity as an active ingredient extracted from an immature persimmon by pressurized hydrothermal method | |
| KR20080079374A (en) | Composition comprising extract of crude drug mixture and the preparation method therof | |
| JP5176176B2 (en) | Improved lipid metabolism, food and drink, and pharmaceuticals | |
| KR101824217B1 (en) | Food composition with Citrus sinensis L. Osbeck and the extract of Irvingia gabonensis seed for improvement of obesity and hyperlipidemia | |
| KR20190113721A (en) | Onion Coat composition Using An Enzyme With Stevia Extract And Method thereof | |
| JP2005320271A (en) | Aldose reductase activity inhibitor, diabetic complication-preventing/treating agent and diabetic complication-preventing/treating food and beverage | |
| JP7239135B2 (en) | α-Glucosidase activity inhibitor and blood sugar elevation inhibitor | |
| WO2019021485A1 (en) | High-gnetin-c-containing melinjo extract and method for producing same | |
| KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
| WO2011080825A1 (en) | Anti-allergic agent | |
| JP2007070267A (en) | Agent for improving lipid metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110830 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120117 |